Avrupa Birliği - İzlandaca - EMA (European Medicines Agency)

ucb pharma sa - brivaracetam - flogaveiki - antiepileptics, - briviact er ætlað sem viðbótarmeðferð við meðhöndlun á flogaveiki með eða án aukakvilla hjá fullorðnum og unglingum frá 16 ára aldri með flogaveiki.

Avrupa Birliği - İzlandaca - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - meloxicam - oxicams - horses; dogs; cattle; cats; pigs; guinea pigs - kettir:lina vægt til í meðallagi eftir aðgerð sársauka og bólgu eftir skurðaðgerðir, e. orthopaedic og mjúkur vefjum skurðaðgerð. lina sársaukann og bólgu í bráð og langvarandi stoðkerfi kvilla. að draga á eftir aðgerð sársauka eftir ovariohysterectomy og minniháttar mjúkur vefjum skurðaðgerð. cattle:for use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs. fyrir að nota í niðurgangur í bland með inntöku aftur vökvun meðferð til að draga úr klínískum merki í kálfa yfir einni viku aldri og ungur, ekki barn á brjósti nautgripum. til að draga úr verkjum eftir aðgerð í kjölfar dehorning í kálfum. til viðbótarmeðferðar við meðferð bráðrar bólgu í munnholi ásamt sýklalyfjameðferð. dogs:alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. minnkun á verkjum og bólgu eftir aðgerð eftir bæklunar og mjúkvefskurðaðgerð. horses:for use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders. til að draga úr sársauka í tengslum við hrossakolbik. lina bólgu og draga úr sársauka í bæði bráð og langvarandi stoðkerfi kvilla. svín: fyrir notkun á ekki smitandi locomotor kvilla til að draga úr einkenni helti og bólgu. til að draga á eftir aðgerð sársauka tengslum með minniháttar mjúkur vefjum aðgerð eins og gelding. til viðbótarmeðferðar við meðhöndlun á blóðsykursfalli og ofnæmisblóðsýringu (bólgusjúkdómur-mígrenisbólga) með viðeigandi sýklalyfjameðferð. naggrísum:lina vægt til í meðallagi eftir aðgerð sársauka tengslum með mjúkum vefjum aðgerð eins og karl gelding.

İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

le vet b.v.* - medetomidinum hýdróklóríð - stungulyf, lausn - 1 mg/ml

İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

cheplapharm arzneimittel gmbh - hydrocortisonum bútýrat - krem - 1 mg/g

İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

boehringer ingelheim vetmedica gmbh* - penethamate hydroiodide ban - stungulyfsstofn og leysir, dreifa - 10.000.000 a.e.

Avrupa Birliği - İzlandaca - EMA (European Medicines Agency)

zoetis belgium sa - meloxicam - anti-inflammatory and anti-rheumatic products, non-steroids - horses; pigs; cattle - cattlefor nota í bráðar sýkingu með viðeigandi sýklalyf meðferð til að draga úr klínískum merki. fyrir að nota í niðurgangur í bland með inntöku aftur vökvun meðferð til að draga úr klínískum merki í kálfa yfir einni viku aldri og ungur, ekki barn á brjósti nautgripum. til viðbótarmeðferðar við meðferð bráðrar bólgu í munnholi ásamt sýklalyfjameðferð. til að draga úr verkjum eftir aðgerð í kjölfar dehorning í kálfum. pigsfor lækkun einkenni helti og bólgu á ekki smitandi locomotor ringulreið og fyrir venjulega meðferð í meðferð sængurkonum blóðeitrun og blóðeitrun (kvenna-legbólgu-agalactia heilkenni) með viðeigandi sýklalyf meðferð. horsesfor nota í lina bólgu og draga úr sársauka í bæði bráð og langvarandi stoðkerfi kvilla. til að draga úr sársauka í tengslum við hrossakolbik.

Avrupa Birliği - İzlandaca - EMA (European Medicines Agency)

merck sharp and dohme b.v - posakónazól - candidiasis; mycoses; coccidioidomycosis; aspergillosis - sveppalyf fyrir almenn nota - noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 og 5. 1):- invasive aspergillosisnoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections  4. 2 og 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. svara ekki meðferð er skilgreint eins og framgangi sýkingu eða bilun til að bæta eftir að minnsta kosti 7 daga áður en lækninga skammta af árangri mikla meðferð. noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4. 2 og 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 og 5. 1):- invasive aspergillosisnoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4. 2 og 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. svara ekki meðferð er skilgreint eins og framgangi sýkingu eða bilun til að bæta eftir að minnsta kosti 7 daga áður en lækninga skammta af árangri mikla meðferð. noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4. 2 og 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (gvhd) and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4. 2 og 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. svara ekki meðferð er skilgreint eins og framgangi sýkingu eða bilun til að bæta eftir að minnsta kosti 7 daga áður en lækninga skammta af árangri mikla meðferð. noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2  years of age:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high  risk of developing invasive fungal infections;- haematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high  risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products;- oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor. svara ekki meðferð er skilgreint eins og framgangi sýkingu eða bilun til að bæta eftir að minnsta kosti 7 daga áður en lækninga skammta af árangri mikla meðferð. noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.

İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

orion corporation - perphenazinum inn - húðuð tafla - 2 mg

İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

ferring lægemidler a/s (f) - docusatum natricum inn; sorbitolum - endaþarmslausn

İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

galderma nordic ab - adapalenum inn - hlaup - 1 mg/g